Alexandria Hammond
Stock Analyst at B of A Securities
(2.82)
# 1,580
Out of 5,182 analysts
15
Total ratings
77.78%
Success rate
14.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Neutral | $570 → $529 | $546.89 | -3.27% | 3 | Feb 20, 2026 | |
| ABBV AbbVie | Downgrades: Peer Perform | n/a | $208.84 | - | 2 | Jan 8, 2026 | |
| MRK Merck & Co. | Upgrades: Outperform | $135 | $120.87 | +11.69% | 2 | Jan 8, 2026 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,150 | $761.85 | +50.95% | 1 | Nov 15, 2024 | |
| PFE Pfizer | Initiates: Underperform | $25 | $28.32 | -11.72% | 1 | Nov 15, 2024 | |
| MRNA Moderna | Initiates: Underperform | $40 | $49.20 | -18.70% | 1 | Nov 15, 2024 | |
| LLY Eli Lilly and Company | Initiates: Outperform | $1,000 | $935.58 | +6.89% | 1 | Nov 15, 2024 | |
| JNJ Johnson & Johnson | Initiates: Outperform | $190 | $243.04 | -21.82% | 1 | Nov 15, 2024 | |
| GILD Gilead Sciences | Initiates: Outperform | $110 | $139.71 | -21.27% | 1 | Nov 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Initiates: Peer Perform | n/a | $59.60 | - | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $177.34 | - | 1 | Nov 15, 2024 |
Madrigal Pharmaceuticals
Feb 20, 2026
Maintains: Neutral
Price Target: $570 → $529
Current: $546.89
Upside: -3.27%
AbbVie
Jan 8, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $208.84
Upside: -
Merck & Co.
Jan 8, 2026
Upgrades: Outperform
Price Target: $135
Current: $120.87
Upside: +11.69%
Regeneron Pharmaceuticals
Nov 15, 2024
Initiates: Outperform
Price Target: $1,150
Current: $761.85
Upside: +50.95%
Pfizer
Nov 15, 2024
Initiates: Underperform
Price Target: $25
Current: $28.32
Upside: -11.72%
Moderna
Nov 15, 2024
Initiates: Underperform
Price Target: $40
Current: $49.20
Upside: -18.70%
Eli Lilly and Company
Nov 15, 2024
Initiates: Outperform
Price Target: $1,000
Current: $935.58
Upside: +6.89%
Johnson & Johnson
Nov 15, 2024
Initiates: Outperform
Price Target: $190
Current: $243.04
Upside: -21.82%
Gilead Sciences
Nov 15, 2024
Initiates: Outperform
Price Target: $110
Current: $139.71
Upside: -21.27%
Bristol-Myers Squibb Company
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $59.60
Upside: -
Nov 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $177.34
Upside: -